NGM Bio Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist Antibody, Coinciding with Publication in Cancer Immunology Research
Publication describes NGM’s discovery of ILT3’s functional ligand, fibronectin, a key component of the tumor…